DEPOTNÍ LÉKOVÉ FORMY V PSYCHOFARMAKOLOGII V KLINICKÝCH A EXPERIMENTÁLNÍCH SOUVISLOSTECH
| Title in English | Depot dosage forms in psychopharmacology in clinical and experimental contexts |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Description | Psychiatric disorders are among chronic diseases that largely affect the quality of life of patients. Thanks to correctly adjusted treatment, patients can be kept in a full life. However, patients are not always willing to adhere to the prescribed therapy, which is why the disease relapses, the subsequent course is more complicated and the patient's prognosis is worse. Parenteral depot dosage forms are gaining importance in psychopharmacology. Their long-term effect is currently used in psychiatric diagnoses due to the frequent non-adherence of patients to therapy. In psychopharmacology in general, nonadherence occurs in approximately half of patients, where it is especially problematic in depression, bipolar disorder and schizophrenia. Based on positive experiences with already existing registered medicines, new long-acting parenteral drug forms are being developed within the framework of inter-institutional cooperation at the Faculty of Pharmacy and at the same time in cooperation with the Pharmacology Institute of the Faculty of Medicine. To date, two drugs have been prepared in the form of microparticles based on the copolymer of lactic acid and glycolic acid (PLGA) for parenteral administration, the antidepressant mirtazapine and the antipsychotic clozapine. |
| Related projects: |